Related Experiment Video
Updated: Jun 5, 2026

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells
Published on: July 16, 2013
Pharmacological modulation of connexin-formed channels in cardiac pathophysiology
Elke De Vuyst1, Kerstin Boengler, Gudrun Antoons
1Department of Basic Medical Sciences - Physiology group, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
Insights
New drugs targeting cardiac gap junctions improve electrical coordination and reduce arrhythmia risk. These compounds enhance communication between heart cells without causing proarrhythmic side effects, offering promise for treating ischaemic cardiomyopathy.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Cardiac electrical activity relies on gap junctions at cardiomyocyte intercalated discs.
- Impaired gap junction communication contributes to re-entry arrhythmias post-myocardial ischaemia.
- Current antiarrhythmic drugs have limited efficacy and side effects.
Purpose of the Study:
- To review compounds that enhance gap junctional communication for novel antiarrhythmic therapy.
- To explore agents that inhibit connexin 43 (Cx43) hemichannels to protect cardiomyocytes during ischaemia/reperfusion.
- To identify drugs with improved safety profiles and reduced proarrhythmic potential.
Main Methods:
- Review of scientific literature on gap junction modulators.
- Focus on compounds including antiarrhythmic peptide (AAP), AAP10, ZP123, GAP-134, RXP-E, Gap 26, and Gap 27.
- Analysis of effects on ion channels and clinical safety data.
Main Results:
- Several compounds increase gap junctional communication, enhancing conduction velocity and reducing arrhythmia risk.
- Some agents inhibit Cx43 hemichannels, limiting ischaemia/reperfusion injury.
- Discussed compounds do not affect Na+, Ca2+, and K+ channels, avoiding proarrhythmic effects.
- GAP-134, RXP-E, Gap 26, and Gap 27 show favorable safety profiles, with GAP-134 confirmed in Phase I trials.
Conclusions:
- Compounds that modulate gap junction communication represent a promising new class of antiarrhythmic drugs.
- These agents offer potential for treating arrhythmias in ischaemic cardiomyopathy with improved safety.
- Targeting gap junctions and hemichannels provides a dual approach to cardiac protection and rhythm management.
Abstract:
Coordinated electrical activity in the heart is supported by gap junction channels located at the intercalated discs of cardiomyocytes. Impaired gap junctional communication between neighbouring cardiomyocytes contributes to the development of re-entry arrhythmias after myocardial ischaemia. Current antiarrhythmic therapy is hampered by a lack of efficiency and side effects, creating the need for a new generation of drugs. In this review, we focus on compounds that increase gap junctional communication, thereby increasing the conduction velocity and decreasing the risk of arrhythmias. Some of these compounds also inhibit connexin 43 (Cx43) hemichannels, thereby limiting adenosine triphosphate loss and volume overload following ischaemia/reperfusion, thus potentially increasing the survival of cardiomyocytes. The compounds discussed in this review are: (i) antiarrythmic peptide (AAP), AAP10, ZP123; (ii) GAP-134; (iii) RXP-E; and (vi) the Cx mimetic peptides Gap 26 and Gap 27. None of these compounds have effects on Na(+) , Ca(2+) and K(+) channels, and therefore have no proarrhythmic activity associated with currently available antiarrhythmic drugs. GAP-134, RXP-E, Gap 26 and Gap 27 are pharmalogical agents with a favorable clinical safety profile, as already confirmed in phase I clinical trials for GAP-134. These agents show an excellent promise for treatment of arrhythmias in patients with ischaemic cardiomyopathy.
Related Concept Videos
Gap Junctions
Gap Junctions
G-Protein Gated Ion Channels
Sensory organs,...
Mechanism of Cardiac Arrhythmias
Pathophysiology of Cardiac Performance
Electrophysiology of Normal Cardiac Rhythm

